The review found no eligible studies for this question.
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).